ALLR [NASD]
Allarity Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.87 Insider Own19.87% Shs Outstand8.29M Perf Week-31.52%
Market Cap11.92M Forward P/E- EPS next Y-1.02 Insider Trans0.00% Shs Float7.44M Perf Month-57.86%
Income- PEG- EPS next Q-0.42 Inst Own3.70% Short Float0.41% Perf Quarter-42.73%
Sales- P/S- EPS this Y-412.60% Inst Trans- Short Ratio0.21 Perf Half Y-88.11%
Book/sh1.78 P/B0.71 EPS next Y45.20% ROA- Target Price8.00 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.10 - 18.20 Perf YTD-87.85%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-93.30% Beta-
Dividend %- Quick Ratio1.40 Sales past 5Y- Gross Margin- 52W Low10.91% ATR0.27
Employees13 Current Ratio1.40 Sales Q/Q- Oper. Margin- RSI (14)34.23 Volatility14.04% 11.98%
OptionableNo Debt/Eq0.07 EPS Q/Q-172.60% Profit Margin- Rel Volume0.55 Prev Close1.26
ShortableYes LT Debt/Eq0.07 Earnings- Payout- Avg Volume147.15K Price1.22
Recom1.00 SMA20-32.03% SMA50-33.13% SMA200-71.20% Volume6,553 Change-3.17%
Jun-29-22 04:01PM  
Jun-15-22 09:25AM  
May-27-22 05:37PM  
May-18-22 05:30PM  
May-16-22 07:40PM  
Apr-22-22 05:00PM  
Mar-15-22 08:32AM  
Feb-18-22 04:15PM  
Jan-21-22 02:30AM  
Jan-03-22 08:00AM  
Dec-22-21 08:00AM  
Dec-21-21 08:00AM  
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.